The guidance is available on flexibilities to help developers of COVID-19 treatments prepare and roll out packaging and labelling for their treatments quickly.
It describes EMA’s criteria for deciding if a COVID-19 treatment can benefit from the same temporary labelling exemptions as COVID-19 vaccines.
Read the pdf